Ivarmacitinib Eased Refractory PCA: Case Report - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

  • By

  • Andrea Surnit

  • May 20, 2026

  • 4 min

Share

  • 1

    A 65-year-old man with refractory primary cutaneous amyloidosis showed rapid improvement after off-label treatment with ivarmacitinib.

  • 2

    The patient experienced significant pruritus relief and lesion improvement within one month of starting ivarmacitinib.

  • 3

    Histopathologic examination confirmed the diagnosis of primary cutaneous amyloidosis, showing characteristic amyloid deposits.

  • 4

    Ivarmacitinib, a selective JAK1 inhibitor, may target multiple inflammatory pathways involved in pruritus and T helper 2 inflammation.

  • 5

    The study highlights the potential of ivarmacitinib for treating isolated primary cutaneous amyloidosis, warranting further research.

Original Source(s)

Ivarmacitinib Eased Refractory PCA: Case Report

  • by Andrea Surnit

  • May 20, 2026

Related Content

Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial